SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has received CE-IVD mark approval for the PD-L1 IHC 28-8 pharmDx to guide options for the first-line ...
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the issuing of a Class C companion diagnostic In Vitro Diagnostic Regulation (IVDR) certification for PD-L1 ...
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration has approved the company’s PD-L1 IHC 22C3 pharmDx as a companion ...
PARP Inhibition in Prostate Cancer With Homologous Recombination Repair Alterations Literature searches were conducted in MEDLINE (via PubMed) and EMBASE to identify studies published between January ...
Hematogenix, an industry leader in the field of integrated pathology services for drug development and clinical testing, announces the availability of the FDA approved PD-L1 companion diagnostic ...
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (A) (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU ...
FDA Approves PD-L1 Companion Diagnostic in Triple-Negative Breast Cancer This past Friday, Agilent Technologies announced it has received approval by the FDA for the use of PD-L1 IHC 22C3 pharmDx as ...
Assay will help guide treatment decisions in cases of non-small cell lung cancer Now, physicians will be able to use the PD-L1 IHC 28-8 pharmDx assay as an aid in identifying patients with metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback